Compositions and Methods for the Treatment of Respiratory Conditions via NKG2D Inhibition
antibody or protein therapy effective at the cellular leveldecreased possibility of side effects due to high selectivity and identification of a specific targetsuitable for treating a number of respiratory conditions, including asthma, steroid-resistant asthma and COPD
treating or preventing respiratory conditions such as asthma, steroid-resistant asthma, and COPD
None
Patent Number: WO2013032943A1
Application Number: WO2012US52369A
Inventor: RAULET, David | HAWORTH, Oliver | LOCKSLEY, Richard | BORCHERS, Michael
Priority Date: 26 Aug 2011
Priority Number: WO2013032943A1
Application Date: 24 Aug 2012
Publication Date: 7 Mar 2013
IPC Current: A61K0039395 | A61K004800 | A61P001100 | A61P001106
Assignee Applicant: The Regents of the University of California
Title: METHODS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY CONDITIONS VIA NKG2D INHIBITION | PROCÉDÉS ET COMPOSITIONS POUR LE TRAITEMENT DE PATHOLOGIES RESPIRATOIRES PAR INHIBITION DE NKG2D
Usefulness: METHODS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY CONDITIONS VIA NKG2D INHIBITION | PROCÉDÉS ET COMPOSITIONS POUR LE TRAITEMENT DE PATHOLOGIES RESPIRATOIRES PAR INHIBITION DE NKG2D
Summary: The method, composition, and kit are useful for treating or preventing a respiratory condition, where the respiratory condition is asthma or chronic obstructive pulmonary disease (COPD) (all claimed).
Novelty: Treating or preventing a respiratory condition comprises administering to the subject a composition comprising an inhibitor of killer cell lectin-like receptor subfamily K, member 1 (NKG2D)-mediated activation of leukocytes
生物医学
医药成分
20140248289
Publication Tech ID/UC Case 22499/2012-099-0 Related Cases 2012-099-0
美国
